Arbutus Biopharma Corp
ABUS · XNASCIK 1447028fmd_1VQNHHZKCX201218TSG6ASBC26Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 58 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 11 | 6 | 6 | 7 | 11 | 39 | 18 | 6 | 14 |
| Realized investment gains (losses) | – | 0 | 25 | – | – | – | – | – | – | – |
| Research and development | 61 | 63 | 58 | 58 | 49 | 66 | 84 | 74 | 54 | 25 |
| Total operating expenses | 493 | 122 | 96 | 150 | 65 | 85 | 104 | 96 | 82 | 52 |
| Operating income | (492) | (111) | (90) | (144) | (58) | (74) | (65) | (78) | (76) | (38) |
| Interest expense | 0 | 0 | 0 | 2 | 4 | 3 | 2 | 0 | 0 | 0 |
| Interest and investment income | 1 | 2 | 3 | 2 | 1 | 0 | 2 | 6 | 7 | 4 |
| Other non-operating income (expense) | 2 | 2 | 28 | (22) | (6) | (3) | 0 | 5 | 6 | 5 |
| Income before taxes | (489) | (109) | (61) | (166) | (64) | (88) | (122) | (103) | (70) | (34) |
| Income tax expense | (105) | (24) | (4) | (13) | 0 | 0 | 4 | 0 | 0 | 0 |
| Net income from continuing operations | (384) | (84) | (57) | (154) | (64) | (88) | (127) | (103) | (70) | (34) |
| Net income | (384) | (84) | (57) | (154) | (64) | (76) | (69) | (73) | (70) | (34) |
| Net income to common shareholders | (384) | (85) | (67) | (165) | (76) | (88) | (69) | – | – | – |